organization · Reporting owner

NOVO HOLDINGS A/S

Disclosed activity across 38 companies

Tapewire entity: 49339
SEC CIK: 0001388325

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arcellx, Inc.ACLX · Entity 15294	10% owner	February 08, 2022	February 09, 2022
CoLucid Pharmaceuticals, Inc.CLCD · Entity 12304	10% owner	September 09, 2016	September 13, 2016
Damora Therapeutics, Inc.GLTO · Entity 4602	10% owner	November 02, 2020	November 05, 2020
Entasis Therapeutics Holdings Inc.ETTX · Entity 16036	10% owner	September 28, 2018	October 01, 2018
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	10% owner	July 22, 2019	July 23, 2019
REATA PHARMACEUTICALS INCRETA · Entity 12293	10% owner	June 22, 2017	June 23, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcellx, Inc.

Report date February 08, 2022 · Filed February 09, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	4,016,878	Ending reported balance After 2022-02-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-02-08 · Conversion · Acquired 3,183,545 · Balance 3,183,545 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date. Row 2 · 2022-02-08 · Purchase · Acquired 833,333 · Balance 4,016,878 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES A PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-02-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-02-08 · Conversion · Disposed 1,550,309 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.
SERIES B-1 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-02-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-02-08 · Conversion · Disposed 666,651 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.
SERIES B-2 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-02-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-02-08 · Conversion · Disposed 533,389 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.
SERIES C PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-02-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-02-08 · Conversion · Disposed 433,196 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

CoLucid Pharmaceuticals, Inc.

Report date September 09, 2016 · Filed September 13, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	3,156,563	Reported balance After 2016-09-09 transaction · row 1 1 source row Row 1 · 2016-09-09 · Purchase · Acquired 100,000 · Balance 3,156,563

Damora Therapeutics, Inc.

Report date November 02, 2020 · Filed November 05, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,497,791	Ending reported balance After 2020-11-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-11-02 · Conversion · Acquired 2,164,458 · Balance 2,164,458 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. Row 2 · 2020-11-02 · Purchase · Acquired 333,333 · Balance 2,497,791 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES B-1 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-02 · Conversion · Disposed 25,562 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES B-2 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-02 · Conversion · Disposed 15,833 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES B-3 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-02 · Conversion · Disposed 63,333 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES B-4 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-02 · Conversion · Disposed 66,666 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES C-1 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-02 · Conversion · Disposed 133,991 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES C-2 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-02 · Conversion · Disposed 194,666 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES C-4 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-02 · Conversion · Disposed 181,688 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES C-5 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-11-02 · Conversion · Disposed 51,911 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES D PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-11-02 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-11-02 · Conversion · Disposed 98,930 · Balance 0 F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3 Preferred Stock, Series B-4 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock at a ratio of 1:2.59970 into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

Entasis Therapeutics Holdings Inc.

Report date September 28, 2018 · Filed October 01, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,181,843	Ending reported balance After 2018-09-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-09-28 · Conversion · Acquired 1,092,008 · Balance 1,092,008 F1: Series B and B-1 redeemable convertible preferred stock (collectively, the "Preferred Stock") has no expiration date and is convertible at any time, at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted into shares of the Issuer's Common Stock based on the Series B Preferred Stock Conversion Price, Series B-1 Tranche A Preferred Stock Conversion Price and Series B-1 Tranche B Preferred Stock Conversion Price (each as defined in the Issuer's Amended and Restated Certificate of Incorporation). F2: Includes 67,440 shares of common stock issued per dividends accrued through September 27, 2018. Row 2 · 2018-09-28 · Purchase · Acquired 1,089,835 · Balance 2,181,843 F3: Represents a purchase from the underwriters in the Issuer's initial public offering.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-09-28 · Conversion · Disposed 7,000,000 · Balance 0 F1: Series B and B-1 redeemable convertible preferred stock (collectively, the "Preferred Stock") has no expiration date and is convertible at any time, at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted into shares of the Issuer's Common Stock based on the Series B Preferred Stock Conversion Price, Series B-1 Tranche A Preferred Stock Conversion Price and Series B-1 Tranche B Preferred Stock Conversion Price (each as defined in the Issuer's Amended and Restated Certificate of Incorporation).
Series B-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-09-28 · Conversion · Disposed 14,237,288 · Balance 0 F1: Series B and B-1 redeemable convertible preferred stock (collectively, the "Preferred Stock") has no expiration date and is convertible at any time, at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted into shares of the Issuer's Common Stock based on the Series B Preferred Stock Conversion Price, Series B-1 Tranche A Preferred Stock Conversion Price and Series B-1 Tranche B Preferred Stock Conversion Price (each as defined in the Issuer's Amended and Restated Certificate of Incorporation).

Filing footnotes · ownership attribution and instrument terms

F1: Series B and B-1 redeemable convertible preferred stock (collectively, the "Preferred Stock") has no expiration date and is convertible at any time, at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted into shares of the Issuer's Common Stock based on the Series B Preferred Stock Conversion Price, Series B-1 Tranche A Preferred Stock Conversion Price and Series B-1 Tranche B Preferred Stock Conversion Price (each as defined in the Issuer's Amended and Restated Certificate of Incorporation).

F2: Includes 67,440 shares of common stock issued per dividends accrued through September 27, 2018.

F3: Represents a purchase from the underwriters in the Issuer's initial public offering.

Mirum Pharmaceuticals, Inc.

Report date July 22, 2019 · Filed July 23, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,445,147	Ending reported balance After 2019-07-22 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-07-22 · Conversion · Acquired 1,870,147 · Balance 1,870,147 F1: Each share of Series A Preferred Stock converted automatically into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Row 2 · 2019-07-22 · Purchase · Acquired 575,000 · Balance 2,445,147 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES A PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-07-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-22 · Conversion · Disposed 1,870,147 · Balance 0 F1: Each share of Series A Preferred Stock converted automatically into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Preferred Stock converted automatically into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

REATA PHARMACEUTICALS INC

Report date June 22, 2017 · Filed June 23, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
CLASS B COMMON STOCKSEC Table II · derivative / convertible security	Direct	1,201,969	Reported balance After 2017-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-06-22 · Sale · Disposed 1,200,000 · Balance 1,201,969 F1: Class B Common Stock has no expiration date and is convertible at the holder's election on a 1-for-1 basis for no additional consideration into the Issuer's Class A Common Stock, at any time. The shares of Class B Common Stock generally converts to shares of Class A Common Stock upon sale or transfer, subject to certain exceptions. F2: Private sale of Class B Common Stock pursuant to a Purchase Agreement dated June 22, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Class B Common Stock has no expiration date and is convertible at the holder's election on a 1-for-1 basis for no additional consideration into the Issuer's Class A Common Stock, at any time. The shares of Class B Common Stock generally converts to shares of Class A Common Stock upon sale or transfer, subject to certain exceptions.

F2: Private sale of Class B Common Stock pursuant to a Purchase Agreement dated June 22, 2017.

Past disclosures · reporting ended (32)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ANAPTYSBIO, INC

Report date August 21, 2017 · Filed August 21, 2017

Section 16 reporting ended · disclosed 2017-08-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,936,604	Reported balance After 2017-08-21 transaction · row 1 1 source row Row 1 · 2017-08-21 · Sale · Disposed 356,300 · Balance 1,936,604 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.10 to $22.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.10 to $22.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Aligos Therapeutics, Inc.

Report date October 20, 2020 · Filed October 22, 2020

Section 16 reporting ended · disclosed 2020-10-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,614,563	Ending reported balance After 2020-10-20 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-10-20 · Conversion · Acquired 2,414,563 · Balance 2,414,563 F1: Each share of Series A Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock automatically converted into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Row 2 · 2020-10-20 · Purchase · Acquired 200,000 · Balance 2,614,563 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES A CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-20 · Conversion · Disposed 1,609,493 · Balance 0 F1: Each share of Series A Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock automatically converted into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.
SERIES B -1 CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-20 · Conversion · Disposed 563,851 · Balance 0 F1: Each share of Series A Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock automatically converted into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.
SERIES B -2 CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-20 · Conversion · Disposed 241,219 · Balance 0 F1: Each share of Series A Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock automatically converted into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock automatically converted into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

Apollo Endosurgery, Inc.

Report date July 24, 2017 · Filed July 26, 2017

Section 16 reporting ended · disclosed 2017-07-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,301,842	Ending reported balance After 2017-07-26 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2017-07-24 · Sale · Disposed 17,200 · Balance 1,334,772 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.7500 to $7.4350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2017-07-25 · Sale · Disposed 24,504 · Balance 1,310,268 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.7750 to $7.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2017-07-26 · Sale · Disposed 8,426 · Balance 1,301,842 F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.7500 to $7.1800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.7500 to $7.4350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.7750 to $7.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.7500 to $7.1800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Avalyn Pharma Inc.

Report date May 01, 2026 · Filed May 05, 2026

Section 16 reporting ended · disclosed 2026-05-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Voting Common StockSEC Table I · non-derivative	Direct	3,883,289	Ending reported balance After 2026-05-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-01 · Conversion · Acquired 3,327,734 · Balance 3,327,734 F1: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. Row 2 · 2026-05-01 · Purchase · Acquired 555,555 · Balance 3,883,289
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-01 · Conversion · Disposed 18,000,000 · Balance 0 F1: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-01 · Conversion · Disposed 1,986,369 · Balance 0 F1: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-01 · Conversion · Disposed 25,899,284 · Balance 0 F1: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.
Series C-2 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-01 · Conversion · Disposed 5,587,603 · Balance 0 F1: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.
Series D Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-01 · Conversion · Disposed 12,558,081 · Balance 0 F1: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.

Bolt Biotherapeutics, Inc.

Report date July 13, 2022 · Filed July 15, 2022

Section 16 reporting ended · disclosed 2022-07-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	3,703,991	Reported balance After 2022-07-13 transaction · row 1 1 source row Row 1 · 2022-07-13 · Sale · Disposed 800,000 · Balance 3,703,991

Checkmate Pharmaceuticals, Inc.

Report date February 23, 2022 · Filed February 25, 2022

Section 16 reporting ended · disclosed 2022-02-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,161,990	Ending reported balance After 2022-02-25 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2022-02-23 · Sale · Disposed 1,820 · Balance 2,168,280 Row 2 · 2022-02-24 · Sale · Disposed 5,990 · Balance 2,162,290 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.79 to $2.91. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price noted in this footnote. Row 3 · 2022-02-25 · Sale · Disposed 300 · Balance 2,161,990

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.79 to $2.91. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price noted in this footnote.

Corvus Pharmaceuticals, Inc.

Report date July 07, 2020 · Filed July 09, 2020

Section 16 reporting ended · disclosed 2020-07-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	1,389,498	Ending reported balance After 2020-07-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-07-07 · Sale · Disposed 796,622 · Balance 2,130,938 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.900 to $5.525, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2020-07-08 · Sale · Disposed 741,440 · Balance 1,389,498 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.020 to $5.810, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.900 to $5.525, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.020 to $5.810, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Cyteir Therapeutics, Inc.

Report date July 19, 2023 · Filed July 20, 2023

Section 16 reporting ended · disclosed 2023-07-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,522,136	Ending reported balance After 2023-07-20 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-07-19 · Sale · Disposed 1,900 · Balance 3,622,136 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2023-07-20 · Sale · Disposed 100,000 · Balance 3,522,136 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Disc Medicine, Inc.

Report date June 28, 2023 · Filed June 28, 2023

Section 16 reporting ended · disclosed 2023-06-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,090,772	Reported balance After 2023-06-28 transaction · row 1 1 source row Row 1 · 2023-06-28 · Sale · Disposed 1,250,000 · Balance 1,090,772

Eargo, Inc.

Report date October 20, 2020 · Filed October 22, 2020

Section 16 reporting ended · disclosed 2020-10-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	887,071	Ending reported balance After 2020-10-20 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-10-20 · Conversion · Acquired 737,071 · Balance 737,071 F1: Each share of Series E Convertible Preferred Stock automatically converted into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Row 2 · 2020-10-20 · Purchase · Acquired 150,000 · Balance 887,071 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES E CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-20 · Conversion · Acquired 737,071 · Balance 0 F1: Each share of Series E Convertible Preferred Stock automatically converted into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series E Convertible Preferred Stock automatically converted into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

Edgewise Therapeutics, Inc.

Report date September 14, 2022 · Filed September 16, 2022

Section 16 reporting ended · disclosed 2022-09-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	6,071,703	Reported balance After 2022-09-14 transaction · row 1 1 source row Row 1 · 2022-09-14 · Purchase · Acquired 484,496 · Balance 6,071,703 F1: Represents a purchase from the underwriters in the Issuer's public offering.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a purchase from the underwriters in the Issuer's public offering.

Galera Therapeutics, Inc.

Report date February 18, 2021 · Filed February 19, 2021

Section 16 reporting ended · disclosed 2021-02-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,459,021	Reported balance After 2021-02-18 transaction · row 1 1 source row Row 1 · 2021-02-18 · Sale · Disposed 500,000 · Balance 2,459,021 F1: The securities were sold as a block sale broker transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The securities were sold as a block sale broker transaction.

HTG MOLECULAR DIAGNOSTICS, INC

Report date August 23, 2017 · Filed August 25, 2017

Section 16 reporting ended · disclosed 2017-08-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	1,102,651	Reported balance After 2017-08-23 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-08-23 · Sale · Disposed 47,162 · Balance 1,102,651 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07, inclusive. Novo Holdings A/S ("Novo") undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: This total does not include 49,786 shares of common stock subject to warrants which were erroneously reported as having been exercised in connection with the Issuer's IPO on a Form 4 filed May 12, 2015. Thus, the holdings of common stock reported by Novo since the May 12, 2015 filing have overstated the total shares held by 49,786 shares.
COMMON STOCKSEC Table I · non-derivative	Direct	720,214	Reported balance After 2017-08-24 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2017-08-24 · Sale · Disposed 382,437 · Balance 720,214 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.900 to $2.045, inclusive. Novo undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
COMMON STOCKSEC Table I · non-derivative	Direct	0	Reported balance After 2017-08-25 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2017-08-25 · Sale · Disposed 720,214 · Balance 0 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.87, inclusive. Novo undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
SERIES E PREFERRED STOCK WARRANTS (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2022-01-14	Direct	49,786	Reported balance Holding disclosure · report date 2017-08-23 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 49,786 F5: These warrants have no expiration date and are convertible at any time at the holder's election. F6: These warrants were erroneously reported as exercised at the time of the IPO on the Form 4 filed May 12, 2015. The warrants are unexercised and, as of the date of this filing, Novo does not hold any shares of common stock but continues to hold the warrants.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07, inclusive. Novo Holdings A/S ("Novo") undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: This total does not include 49,786 shares of common stock subject to warrants which were erroneously reported as having been exercised in connection with the Issuer's IPO on a Form 4 filed May 12, 2015. Thus, the holdings of common stock reported by Novo since the May 12, 2015 filing have overstated the total shares held by 49,786 shares.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.900 to $2.045, inclusive. Novo undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.87, inclusive. Novo undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5: These warrants have no expiration date and are convertible at any time at the holder's election.

F6: These warrants were erroneously reported as exercised at the time of the IPO on the Form 4 filed May 12, 2015. The warrants are unexercised and, as of the date of this filing, Novo does not hold any shares of common stock but continues to hold the warrants.

Harmony Biosciences Holdings, Inc.

Report date August 21, 2020 · Filed September 04, 2020 · Amendment

Section 16 reporting ended · disclosed 2020-09-04. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	3,754,973	Reported balance After 2020-08-21 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2020-08-21 · Conversion · Acquired 3,622,470 · Balance 3,754,973 F1: This amendment reflects the updated dividend shares issuable on the preferred stock as communicated to Novo Holdings A/S by the Issuer on August 31, 2020. The Series A Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted on a 8.215-for-1 basis into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment or further consideration. The number of shares of Common Stock shown in Column 7 also includes the payment of an accrued stock dividend by the Company to the holder which became due and issuable upon the conversion of the convertible preferred stock. These shares have no expiration date.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-08-21 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2020-08-21 · Conversion · Disposed 25,000,000 · Balance 0 F1: This amendment reflects the updated dividend shares issuable on the preferred stock as communicated to Novo Holdings A/S by the Issuer on August 31, 2020. The Series A Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted on a 8.215-for-1 basis into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment or further consideration. The number of shares of Common Stock shown in Column 7 also includes the payment of an accrued stock dividend by the Company to the holder which became due and issuable upon the conversion of the convertible preferred stock. These shares have no expiration date.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-08-21 transaction · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · 2020-08-21 · Conversion · Disposed 1,860,107 · Balance 0 F1: This amendment reflects the updated dividend shares issuable on the preferred stock as communicated to Novo Holdings A/S by the Issuer on August 31, 2020. The Series A Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted on a 8.215-for-1 basis into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment or further consideration. The number of shares of Common Stock shown in Column 7 also includes the payment of an accrued stock dividend by the Company to the holder which became due and issuable upon the conversion of the convertible preferred stock. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: This amendment reflects the updated dividend shares issuable on the preferred stock as communicated to Novo Holdings A/S by the Issuer on August 31, 2020. The Series A Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted on a 8.215-for-1 basis into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment or further consideration. The number of shares of Common Stock shown in Column 7 also includes the payment of an accrued stock dividend by the Company to the holder which became due and issuable upon the conversion of the convertible preferred stock. These shares have no expiration date.

Hemab Therapeutics Holdings, Inc.

Report date May 04, 2026 · Filed May 06, 2026

Section 16 reporting ended · disclosed 2026-05-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,180,550	Reported balance After 2026-05-04 transaction · row 1 1 source row Row 1 · 2026-05-04 · Conversion · Acquired 4,180,550 · Balance 4,180,550 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Series Seed Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-04 · Conversion · Disposed 23,343 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-04 · Conversion · Disposed 71,866 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-04 · Conversion · Disposed 62,121 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-04 · Conversion · Disposed 32,695 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.

IO Biotech, Inc.

Report date July 25, 2024 · Filed July 27, 2024

Section 16 reporting ended · disclosed 2024-07-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	4,354,449	Ending reported balance After 2024-07-26 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-07-25 · Sale · Disposed 51,522 · Balance 4,377,927 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2024-07-26 · Sale · Disposed 23,478 · Balance 4,354,449 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

IVERIC bio, Inc.

Report date December 14, 2016 · Filed December 16, 2016

Section 16 reporting ended · disclosed 2016-12-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2016-12-15 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2016-12-14 · Sale · Disposed 2,205,000 · Balance 1,405,487 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.87 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2016-12-15 · Sale · Disposed 1,405,487 · Balance 0 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.53 to $4.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.87 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.53 to $4.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Inogen Inc

Report date June 02, 2021 · Filed June 03, 2021

Section 16 reporting ended · disclosed 2021-06-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,079,320	Reported balance After 2021-06-02 transaction · row 1 1 source row Row 1 · 2021-06-02 · Sale · Disposed 680,000 · Balance 2,079,320 F1: The securities were sold as a block sale broker transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The securities were sold as a block sale broker transaction.

Inozyme Pharma, Inc.

Report date January 28, 2021 · Filed February 01, 2021

Section 16 reporting ended · disclosed 2021-02-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,194,379	Reported balance After 2021-01-28 transaction · row 1 1 source row Row 1 · 2021-01-28 · Sale · Disposed 375,000 · Balance 2,194,379 F1: The securities were sold as a block sale broker transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The securities were sold as a block sale broker transaction.

KalVista Pharmaceuticals, Inc.

Report date October 10, 2017 · Filed October 12, 2017

Section 16 reporting ended · disclosed 2017-10-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2017-10-12 transaction · row 9 9 source rows · reconciled sequence Row 1 · 2017-10-10 · Sale · Disposed 413,356 · Balance 2,311,927 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2017-10-10 · Sale · Disposed 190,981 · Balance 2,120,946 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2017-10-10 · Sale · Disposed 165,199 · Balance 1,955,747 F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2017-10-10 · Sale · Disposed 61,044 · Balance 1,894,703 F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 5 · 2017-10-10 · Sale · Disposed 57,580 · Balance 1,837,123 F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 6 · 2017-10-10 · Sale · Disposed 75,123 · Balance 1,762,000 F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 7 · 2017-10-11 · Sale · Disposed 35,519 · Balance 1,726,481 F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 8 · 2017-10-12 · Sale · Disposed 481 · Balance 1,726,000 Row 9 · 2017-10-12 · Sale · Disposed 1,726,000 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

MINERVA SURGICAL INC

Report date October 26, 2021 · Filed October 27, 2021

Section 16 reporting ended · disclosed 2021-10-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,057,132	Ending reported balance After 2021-10-26 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2021-10-26 · Conversion · Acquired 884,484 · Balance 884,484 F1: The Series D Redeemable Convertible Preferred Stock converted into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's initial public offering ("IPO") without payment of further consideration. These shares have no expiration date. Row 2 · 2021-10-26 · Conversion · Acquired 592,648 · Balance 1,477,132 F2: The Subordinated Secured Convertible Promissory Notes converted into preferred stock, which converts into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's IPO without payment of further consideration. The notes have a maturity date of June 30, 2023. Row 3 · 2021-10-26 · Purchase · Acquired 580,000 · Balance 2,057,132 F3: Represents a purchase from the underwriters in the Issuer's IPO.
SERIES D REDEEMABLE CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-26 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-10-26 · Conversion · Disposed 884,484 · Balance 0 F1: The Series D Redeemable Convertible Preferred Stock converted into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's initial public offering ("IPO") without payment of further consideration. These shares have no expiration date.
SUBORDINATED SECURED CONVERTIBLE PROMISSORY NOTESSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-26 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-10-26 · Conversion · Disposed Not disclosed · Balance 0 F2: The Subordinated Secured Convertible Promissory Notes converted into preferred stock, which converts into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's IPO without payment of further consideration. The notes have a maturity date of June 30, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: The Series D Redeemable Convertible Preferred Stock converted into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's initial public offering ("IPO") without payment of further consideration. These shares have no expiration date.

F2: The Subordinated Secured Convertible Promissory Notes converted into preferred stock, which converts into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's IPO without payment of further consideration. The notes have a maturity date of June 30, 2023.

F3: Represents a purchase from the underwriters in the Issuer's IPO.

MapLight Therapeutics, Inc.

Report date October 28, 2025 · Filed October 30, 2025

Section 16 reporting ended · disclosed 2025-10-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Voting Common StockSEC Table I · non-derivative	Direct	3,686,622	Ending reported balance After 2025-10-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-10-28 · Conversion · Acquired 2,733,681 · Balance 2,733,681 F1: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. Row 2 · 2025-10-28 · Purchase · Acquired 952,941 · Balance 3,686,622 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-10-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-28 · Conversion · Disposed 26,191,207 · Balance 0 F1: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
Series D Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-10-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-28 · Conversion · Disposed 19,734,671 · Balance 0 F1: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

Metagenomi Therapeutics, Inc.

Report date February 09, 2024 · Filed February 16, 2024

Section 16 reporting ended · disclosed 2024-02-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	1,739,175	Ending reported balance After 2024-02-13 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-02-09 · Purchase · Acquired 100,000 · Balance 100,000 Row 2 · 2024-02-13 · Conversion · Acquired 839,175 · Balance 939,175 F1: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. Row 3 · 2024-02-13 · Purchase · Acquired 800,000 · Balance 1,739,175 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES B PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-13 · Conversion · Disposed 147,415 · Balance 0 F1: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
SERIES B-1 PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-13 · Conversion · Disposed 691,760 · Balance 0 F1: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

Milestone Pharmaceuticals Inc.

Report date November 25, 2019 · Filed November 27, 2019

Section 16 reporting ended · disclosed 2019-11-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON SHARESSEC Table I · non-derivative	Direct	2,434,470	Reported balance After 2019-11-25 transaction · row 1 1 source row Row 1 · 2019-11-25 · Sale · Disposed 240,000 · Balance 2,434,470 F1: The securities were sold as a block sale broker transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The securities were sold as a block sale broker transaction.

Morphic Holding, Inc.

Report date June 28, 2019 · Filed July 01, 2019

Section 16 reporting ended · disclosed 2019-07-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,645,446	Ending reported balance After 2019-06-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-06-28 · Conversion · Acquired 1,978,779 · Balance 1,978,779 F1: Each share of Series B Convertible Preferred Stock converted automatically into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Row 2 · 2019-06-28 · Purchase · Acquired 666,667 · Balance 2,645,446 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES B CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-06-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-06-28 · Conversion · Disposed 1,978,779 · Balance 0 F1: Each share of Series B Convertible Preferred Stock converted automatically into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Convertible Preferred Stock converted automatically into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

Nkarta, Inc.

Report date July 14, 2020 · Filed July 16, 2020

Section 16 reporting ended · disclosed 2020-07-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,793,865	Ending reported balance After 2020-07-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-07-14 · Conversion · Acquired 2,238,310 · Balance 2,238,310 F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date. Row 2 · 2020-07-14 · Purchase · Acquired 555,555 · Balance 2,793,865 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES A CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-14 · Conversion · Disposed 525,499 · Balance 0 F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.
SERIES B CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-14 · Conversion · Disposed 1,712,811 · Balance 0 F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

OnKure Therapeutics, Inc.

Report date June 23, 2023 · Filed June 23, 2023

Section 16 reporting ended · disclosed 2023-06-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,330,337	Reported balance After 2023-06-23 transaction · row 1 1 source row Row 1 · 2023-06-23 · Sale · Disposed 100,000 · Balance 3,330,337 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.93 to $7.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.93 to $7.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Praxis Precision Medicines, Inc.

Report date October 20, 2020 · Filed October 21, 2020

Section 16 reporting ended · disclosed 2020-10-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,442,080	Reported balance After 2020-10-20 transaction · row 1 1 source row Row 1 · 2020-10-20 · Conversion · Acquired 2,442,080 · Balance 2,442,080 F1: The Series B Redeemable Convertible Preferred Stock, Series B-1 Redeemable Convertible Preferred Stock, Series C Redeemable Convertible Preferred Stock and Series C-1 Redeemable Convertible Preferred Stock automatically converted on a 2.14-for-1 basis into the number of shares of common stock as shown in Column 7 upon the completion of the Issuer's initial public offering without payment of further consideration. The preferred stock had no expiration date.
SERIES B REDEEMABLE CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-10-20 · Conversion · Disposed 4,150,000 · Balance 0 F1: The Series B Redeemable Convertible Preferred Stock, Series B-1 Redeemable Convertible Preferred Stock, Series C Redeemable Convertible Preferred Stock and Series C-1 Redeemable Convertible Preferred Stock automatically converted on a 2.14-for-1 basis into the number of shares of common stock as shown in Column 7 upon the completion of the Issuer's initial public offering without payment of further consideration. The preferred stock had no expiration date.
SERIES B-1 REDEEMABLE CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-20 · Conversion · Disposed 551,794 · Balance 0 F1: The Series B Redeemable Convertible Preferred Stock, Series B-1 Redeemable Convertible Preferred Stock, Series C Redeemable Convertible Preferred Stock and Series C-1 Redeemable Convertible Preferred Stock automatically converted on a 2.14-for-1 basis into the number of shares of common stock as shown in Column 7 upon the completion of the Issuer's initial public offering without payment of further consideration. The preferred stock had no expiration date.
SERIES C REDEEMABLE CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-20 · Conversion · Disposed 171,410 · Balance 0 F1: The Series B Redeemable Convertible Preferred Stock, Series B-1 Redeemable Convertible Preferred Stock, Series C Redeemable Convertible Preferred Stock and Series C-1 Redeemable Convertible Preferred Stock automatically converted on a 2.14-for-1 basis into the number of shares of common stock as shown in Column 7 upon the completion of the Issuer's initial public offering without payment of further consideration. The preferred stock had no expiration date.
SERIES C-1 REDEEMABLE CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-20 · Conversion · Disposed 352,734 · Balance 0 F1: The Series B Redeemable Convertible Preferred Stock, Series B-1 Redeemable Convertible Preferred Stock, Series C Redeemable Convertible Preferred Stock and Series C-1 Redeemable Convertible Preferred Stock automatically converted on a 2.14-for-1 basis into the number of shares of common stock as shown in Column 7 upon the completion of the Issuer's initial public offering without payment of further consideration. The preferred stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The Series B Redeemable Convertible Preferred Stock, Series B-1 Redeemable Convertible Preferred Stock, Series C Redeemable Convertible Preferred Stock and Series C-1 Redeemable Convertible Preferred Stock automatically converted on a 2.14-for-1 basis into the number of shares of common stock as shown in Column 7 upon the completion of the Issuer's initial public offering without payment of further consideration. The preferred stock had no expiration date.

Ra Pharmaceuticals, Inc.

Report date October 31, 2016 · Filed November 02, 2016

Section 16 reporting ended · disclosed 2016-11-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,031,562	Ending reported balance After 2016-10-31 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2016-10-31 · Conversion · Acquired 924,970 · Balance 924,970 F1: The Series B-1 Preferred Stock and Series B-2 Preferred Stock (the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock. Row 2 · 2016-10-31 · Conversion · Acquired 860,438 · Balance 1,785,408 F1: The Series B-1 Preferred Stock and Series B-2 Preferred Stock (the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock. Row 3 · 2016-10-31 · Purchase · Acquired 246,154 · Balance 2,031,562 F2: Represents a purchase from the underwriters in the Issuer's public offering.
Series B-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-31 · Conversion · Disposed 924,970 · Balance 0 F1: The Series B-1 Preferred Stock and Series B-2 Preferred Stock (the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.
Series B-2 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-31 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-10-31 · Conversion · Disposed 860,438 · Balance 0 F1: The Series B-1 Preferred Stock and Series B-2 Preferred Stock (the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.

Filing footnotes · ownership attribution and instrument terms

F1: The Series B-1 Preferred Stock and Series B-2 Preferred Stock (the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.

F2: Represents a purchase from the underwriters in the Issuer's public offering.

SPRUCE BIOSCIENCES, INC.

Report date March 21, 2024 · Filed March 26, 2024

Section 16 reporting ended · disclosed 2024-03-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	2,550,000	Reported balance After 2024-03-21 transaction · row 1 1 source row Row 1 · 2024-03-21 · Sale · Disposed 465,021 · Balance 2,550,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.71 to $0.7785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.71 to $0.7785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Verve Therapeutics, Inc.

Report date June 21, 2021 · Filed June 22, 2021

Section 16 reporting ended · disclosed 2021-06-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	793,265	Ending reported balance After 2021-06-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-06-21 · Conversion · Acquired 443,265 · Balance 443,265 F1: Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date. Row 2 · 2021-06-21 · Purchase · Acquired 350,000 · Balance 793,265 F2: Represents a purchase from the underwriters in the Issuer's initial public offering.
SERIES B CONVERTIBLE PREFERRED STOCKSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-06-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-06-21 · Conversion · Disposed 443,265 · Balance 0 F1: Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.

iRhythm Holdings, Inc.

Report date October 25, 2016 · Filed October 26, 2016

Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,124,448	Ending reported balance After 2016-10-25 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2016-10-25 · Conversion · Acquired 2,007,449 · Balance 2,024,448 F1: The Series E Preferred Stock (the "Preferred Stock") had no expiration date. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock. Row 2 · 2016-10-25 · Purchase · Acquired 100,000 · Balance 2,124,448 F2: Represents a purchase from the underwriters in the Issuer's public offering.
Series E Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Conversion · Disposed 2,007,449 · Balance 0 F1: The Series E Preferred Stock (the "Preferred Stock") had no expiration date. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.

Filing footnotes · ownership attribution and instrument terms

F1: The Series E Preferred Stock (the "Preferred Stock") had no expiration date. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.

F2: Represents a purchase from the underwriters in the Issuer's public offering.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 04, 2026 Filed May 6, 2026 20:55 UTC	Hemab Therapeutics Holdings, Inc. COAG · Entity 4476	ConversionSeries C Preferred Stock · Derivative	32,695	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000023 · form4-05062026_080518.xml · derivative · entry 5 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 719,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. Read SEC document
May 04, 2026 Filed May 6, 2026 20:55 UTC	Hemab Therapeutics Holdings, Inc. COAG · Entity 4476	ConversionSeries B Preferred Stock · Derivative	62,121	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000023 · form4-05062026_080518.xml · derivative · entry 4 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,366,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. Read SEC document
May 04, 2026 Filed May 6, 2026 20:55 UTC	Hemab Therapeutics Holdings, Inc. COAG · Entity 4476	ConversionSeries A Preferred Stock · Derivative	71,866	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000023 · form4-05062026_080518.xml · derivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,581,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. Read SEC document
May 04, 2026 Filed May 6, 2026 20:55 UTC	Hemab Therapeutics Holdings, Inc. COAG · Entity 4476	ConversionSeries Seed Preferred Stock · Derivative	23,343	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000023 · form4-05062026_080518.xml · derivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 513,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. Read SEC document
May 04, 2026 Filed May 6, 2026 20:55 UTC	Hemab Therapeutics Holdings, Inc. COAG · Entity 4476	ConversionCommon Stock	4,180,550	Not disclosed	Not disclosed	Disclosure SEC source: 0001388325-26-000023 · form4-05062026_080518.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,180,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date. Read SEC document
May 01, 2026 Filed May 5, 2026 20:15 UTC	Avalyn Pharma Inc. AVLN · Entity 4662	ConversionSeries D Preferred Stock · Derivative	12,558,081	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000021 · form4-05052026_040501.xml · derivative · entry 7 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Stock · 652,649 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. Read SEC document
May 01, 2026 Filed May 5, 2026 20:15 UTC	Avalyn Pharma Inc. AVLN · Entity 4662	ConversionSeries C-2 Preferred Stock · Derivative	5,587,603	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000021 · form4-05052026_040501.xml · derivative · entry 6 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Stock · 290,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. Read SEC document
May 01, 2026 Filed May 5, 2026 20:15 UTC	Avalyn Pharma Inc. AVLN · Entity 4662	ConversionSeries C-1 Preferred Stock · Derivative	25,899,284	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000021 · form4-05052026_040501.xml · derivative · entry 5 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Stock · 1,345,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. Read SEC document
May 01, 2026 Filed May 5, 2026 20:15 UTC	Avalyn Pharma Inc. AVLN · Entity 4662	ConversionSeries B Preferred Stock · Derivative	1,986,369	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000021 · form4-05052026_040501.xml · derivative · entry 4 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Stock · 103,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. Read SEC document
May 01, 2026 Filed May 5, 2026 20:15 UTC	Avalyn Pharma Inc. AVLN · Entity 4662	ConversionSeries A Preferred Stock · Derivative	18,000,000	$0.00	$0.00	Disclosure SEC source: 0001388325-26-000021 · form4-05052026_040501.xml · derivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Stock · 935,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. Read SEC document
May 01, 2026 Filed May 5, 2026 20:15 UTC	Avalyn Pharma Inc. AVLN · Entity 4662	PurchaseVoting Common Stock	555,555	$18.00	$9,999,990.00	Disclosure SEC source: 0001388325-26-000021 · form4-05052026_040501.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,883,289 Read SEC document
May 01, 2026 Filed May 5, 2026 20:15 UTC	Avalyn Pharma Inc. AVLN · Entity 4662	ConversionVoting Common Stock	3,327,734	Not disclosed	Not disclosed	Disclosure SEC source: 0001388325-26-000021 · form4-05052026_040501.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,327,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date. Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:31 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	ConversionSeries D Preferred Stock · Derivative	19,734,671	$0.00	$0.00	Disclosure SEC source: 0001388325-25-000018 · form4-10302025_081039.xml · derivative · entry 4 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Stock · 1,174,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:31 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	ConversionSeries C Preferred Stock · Derivative	26,191,207	$0.00	$0.00	Disclosure SEC source: 0001388325-25-000018 · form4-10302025_081039.xml · derivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Voting Common Stock · 1,558,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:31 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	PurchaseVoting Common Stock	952,941	$17.00	$16,199,997.00	Disclosure SEC source: 0001388325-25-000018 · form4-10302025_081039.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,686,622 F2 · shares: Represents a purchase from the underwriters in the Issuer's initial public offering. Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:31 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	ConversionVoting Common Stock	2,733,681	Not disclosed	Not disclosed	Disclosure SEC source: 0001388325-25-000018 · form4-10302025_081039.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,733,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. Read SEC document
July 26, 2024 Filed Jul 27, 2024 01:22 UTC	IO Biotech, Inc. IOBT · Entity 8764	SaleCOMMON STOCK	23,478	$1.31	$30,786.70	Disclosure SEC source: 0000950170-24-087061 · ownership.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,354,449 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 25, 2024 Filed Jul 27, 2024 01:22 UTC	IO Biotech, Inc. IOBT · Entity 8764	SaleCOMMON STOCK	51,522	$1.33	$68,338.78	Disclosure SEC source: 0000950170-24-087061 · ownership.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,377,927 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
May 10, 2024 Filed May 15, 2024 01:13 UTC	IO Biotech, Inc. IOBT · Entity 8764	SaleCOMMON STOCK	658,809	$1.22	$802,495.24	Disclosure SEC source: 0000950170-24-059965 · ownership.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,429,449 Read SEC document
March 21, 2024 Filed Mar 26, 2024 01:45 UTC	SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471	SaleCOMMON STOCK	465,021	$0.75	$350,951.35	Disclosure SEC source: 0001209191-24-005075 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,550,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.71 to $0.7785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 20, 2024 Filed Mar 21, 2024 00:56 UTC	SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471	SaleCOMMON STOCK	359,979	$0.73	$264,080.59	Disclosure SEC source: 0001209191-24-005017 · doc4.xml · nonDerivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,015,021 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7110 to $0.7633, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 19, 2024 Filed Mar 21, 2024 00:56 UTC	SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471	SaleCOMMON STOCK	593,000	$0.76	$447,715.00	Disclosure SEC source: 0001209191-24-005017 · doc4.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,375,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7105 to $0.7887, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 18, 2024 Filed Mar 21, 2024 00:56 UTC	SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471	SaleCOMMON STOCK	842,020	$0.77	$647,008.17	Disclosure SEC source: 0001209191-24-005017 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,968,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.75 to $0.8004, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 14, 2024 Filed Mar 19, 2024 01:14 UTC	SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471	SaleCOMMON STOCK	1,912,316	$0.89	$1,698,901.53	Disclosure SEC source: 0001209191-24-004900 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,810,020 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $1.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 13, 2024 Filed Feb 16, 2024 01:38 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionSERIES B-1 PREFERRED STOCK · Derivative	691,760	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-003423 · doc4.xml · derivative · entry 5 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 691,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. F1 · price: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. Read SEC document
February 13, 2024 Filed Feb 16, 2024 01:38 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionSERIES B PREFERRED STOCK · Derivative	147,415	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-003423 · doc4.xml · derivative · entry 4 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 147,415 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. F1 · price: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. Read SEC document
February 13, 2024 Filed Feb 16, 2024 01:38 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	PurchaseCOMMON STOCK	800,000	$15.00	$12,000,000.00	Disclosure SEC source: 0001209191-24-003423 · doc4.xml · nonDerivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,739,175 F2 · shares: Represents a purchase from the underwriters in the Issuer's initial public offering. Read SEC document
February 13, 2024 Filed Feb 16, 2024 01:38 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionCOMMON STOCK	839,175	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-003423 · doc4.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 939,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. Read SEC document
February 09, 2024 Filed Feb 14, 2024 02:31 UTC	IO Biotech, Inc. IOBT · Entity 8764	SaleCOMMON STOCK	658,809	$1.50	$988,411.14	Disclosure SEC source: 0001209191-24-003303 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,088,258 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 09, 2024 Filed Feb 16, 2024 01:38 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	PurchaseCOMMON STOCK	100,000	$10.25	$1,025,000.00	Disclosure SEC source: 0001209191-24-003423 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Read SEC document
August 09, 2023 Filed Aug 11, 2023 20:31 UTC	IO Biotech, Inc. IOBT · Entity 8764	PurchaseCommon Stock Warrant (Right to Buy) · Derivative	2,469,135	$2.03 Strike: $2.47	$4,999,998.38	Disclosure SEC source: 0001209191-23-045444 · doc4.xml · derivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,469,135 Underlying: Common Stock · 2,469,135 shares Expires 2027-02-09 F1 · price: Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement. Read SEC document
August 09, 2023 Filed Aug 11, 2023 20:31 UTC	IO Biotech, Inc. IOBT · Entity 8764	PurchaseCommon Stock	2,469,135	$2.03	$4,999,998.38	Disclosure SEC source: 0001209191-23-045444 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,707,467 F1 · price: Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement. Read SEC document
July 20, 2023 Filed Jul 20, 2023 20:01 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	100,000	$2.75	$275,140.00	Disclosure SEC source: 0001209191-23-042977 · doc4.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,522,136 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 19, 2023 Filed Jul 20, 2023 20:01 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	1,900	$2.76	$5,247.04	Disclosure SEC source: 0001209191-23-042977 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,622,136 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 18, 2023 Filed Jul 18, 2023 20:27 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	6,500	$2.76	$17,923.10	Disclosure SEC source: 0001209191-23-042670 · doc4.xml · nonDerivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,624,036 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.73 to $2.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 17, 2023 Filed Jul 18, 2023 20:27 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	21,100	$2.75	$57,999.68	Disclosure SEC source: 0001209191-23-042670 · doc4.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,630,536 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.74 to $2.7498, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 14, 2023 Filed Jul 18, 2023 20:27 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	11,000	$2.74	$30,101.50	Disclosure SEC source: 0001209191-23-042670 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,651,636 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.73 to $2.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
June 30, 2023 Filed Jul 3, 2023 18:29 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	200,937	$2.63	$529,288.15	Disclosure SEC source: 0001209191-23-040691 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,662,636 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.61 to $2.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 28, 2023 Filed Jun 28, 2023 21:04 UTC	Disc Medicine, Inc. IRON · Entity 2273	SaleCommon Stock	1,250,000	$46.10	$57,625,000.00	Disclosure SEC source: 0001209191-23-040057 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,090,772 Read SEC document
June 27, 2023 Filed Jun 28, 2023 21:35 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	31,978	$1.77	$56,687.40	Disclosure SEC source: 0001209191-23-040129 · doc4.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,863,573 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.67 to $1.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 26, 2023 Filed Jun 28, 2023 21:35 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	8,437	$1.79	$15,106.45	Disclosure SEC source: 0001209191-23-040129 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,895,551 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.70 to $1.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 23, 2023 Filed Jun 23, 2023 19:17 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	3,423	$1.88	$6,446.88	Disclosure SEC source: 0001209191-23-039545 · doc4.xml · nonDerivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,903,988 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.86 to $1.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 23, 2023 Filed Jun 23, 2023 23:15 UTC	OnKure Therapeutics, Inc. RPHM · Entity 6550	SaleCommon Stock	100,000	$7.10	$709,740.00	Disclosure SEC source: 0001209191-23-039541 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,330,337 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.93 to $7.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 22, 2023 Filed Jun 23, 2023 19:17 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	5,041	$1.94	$9,782.56	Disclosure SEC source: 0001209191-23-039545 · doc4.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,907,411 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $2.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 21, 2023 Filed Jun 23, 2023 19:17 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	4,834	$1.99	$9,640.93	Disclosure SEC source: 0001209191-23-039545 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,912,452 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.98 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 20, 2023 Filed Jun 20, 2023 17:53 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	744	$2.11	$1,573.19	Disclosure SEC source: 0001209191-23-038567 · doc4.xml · nonDerivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,917,286 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1036 to $2.1223, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 16, 2023 Filed Jun 20, 2023 17:53 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	5,983	$2.03	$12,141.90	Disclosure SEC source: 0001209191-23-038567 · doc4.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,918,030 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.98 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 15, 2023 Filed Jun 20, 2023 17:53 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	10,002	$2.03	$20,304.06	Disclosure SEC source: 0001209191-23-038567 · doc4.xml · nonDerivative · entry 1 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,924,013 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.00 to $2.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 14, 2023 Filed Jun 14, 2023 20:18 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	2,872	$2.11	$6,050.16	Disclosure SEC source: 0001209191-23-037208 · doc4.xml · nonDerivative · entry 3 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,934,015 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 13, 2023 Filed Jun 14, 2023 20:18 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	SaleCommon Stock	2,626	$2.10	$5,514.60	Disclosure SEC source: 0001209191-23-037208 · doc4.xml · nonDerivative · entry 2 Novo Holdings A/S · CIK 0001388325 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,936,887 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.